The Centers for Disease Control and Prevention yesterday issued a health advisory warning of an uptick over the last year in meningococcal disease in which isolates show the gene associated with penicillin resistance and mutations associated with ciprofloxacin resistance.

CDC said the majority of cases were in Hispanic individuals.

The agency recommends the following for providers and clinicians:

  • Health care providers should perform antimicrobial susceptibility testing to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
  • In states that have experienced meningococcal disease cases caused by ciprofloxacin-resistant strains within the past 1–2 years, clinicians and public health staff should consider AST on meningococcal isolates to inform prophylaxis decisions. AST should not delay the initiation of prophylaxis with ciprofloxacin, rifampin or ceftriaxone.

Related News Articles

Headline
In this conversation, Terry Scoggin, CEO of Titus Regional Medical Center, discusses how the organization designed a system of care to ensure that every…
Headline
The Department of Health and Human Services Dec. 11 published a final rule implementing provisions related to the Trusted Exchange Framework and Common…
Headline
In this conversation, Dave Eaker, geriatric program manager at Atrium Health, and Shannon Morton, assistant vice president of patient care services at Atrium…
Headline
In this conversation, Jennifer Richards, Ph.D., assistant professor at the Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, and…
Headline
Registration is now open for AHA's 2025 Accelerating Health Equity Conference, May 19-22 in Atlanta, with an early-bird discount period through March 31. Join…
Headline
In this conversation, Kimberly Wozneak, national lead for age-friendly health systems at the Department of Veterans Affairs, discusses how the Veterans Health…